Use of Tecovirimat (TPOXX ) for Treatment of Human Orthopoxvirus Infections
Recruiting
99 years or below
All
1 Location
Brief description of study
The purpose of this study is to test the use of Tecovirimat (TPOXX ) for Treatment of Human Orthopoxvirus Infections.
Tecovirimat (also known as TPOXX or ST-246) is a drug that may help to treat infections caused by pox viruses and reactions to the smallpox vaccine.
Eligible Participants:
• Have or may have been exposed to a pox virus (such as cowpox or monkeypox) and have
developed or may be at risk of developing a serious or life-threatening infection.
OR
• Have or may have been exposed to vaccinia (the virus in one of the smallpox vaccines that contains
live virus) through getting the vaccine, contact with another person who got the smallpox vaccine, or
some other way, and have developed a serious reaction.
Detailed description of study
The purpose of this study is to test the use of Tecovirimat (TPOXX ) for Treatment of Human Orthopoxvirus Infections.
Tecovirimat (also known as TPOXX or ST-246) is a drug that may help to treat infections caused by pox viruses and reactions to the smallpox vaccine.
Eligible Participants:
• Have or may have been exposed to a pox virus (such as cowpox or monkeypox) and have
developed or may be at risk of developing a serious or life-threatening infection.
OR
• Have or may have been exposed to vaccinia (the virus in one of the smallpox vaccines that contains
live virus) through getting the vaccine, contact with another person who got the smallpox vaccine, or
some other way, and have developed a serious reaction.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research, Human Orthopoxvirus Infections
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 851529
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
